BACKGROUND: The aim of this study is to compare the clinical outcome in T2 @entity0 @entity1 who underwent preoperative chemotherapy (PC) and who did not. The study also tried to define a subgroup of @entity1 , who are more beneficial after PC in terms of lower re-excision rates, better cosmetic results and local recurrence free survival. MATERIALS AND METHODS: 251 consecutive @entity1 treated for nonmetastatic T2 invasive @entity0 were analyzed retrospectively. Of those; 141 underwent primary surgery (PS) followed by chemotherapy, whereas 110 were treated with combination of PC and surgery. RESULTS: The @entity1 who were treated with PC had a significantly higher incidence of negative margins and lower rate of re-excision (5% vs. 16%, p  =  0.02). Of all @entity1 attempted breast conserving surgery (BCS), @entity1 in the PC group were more likely to undergo BCS as their definitive operation compared to @entity1 with PS group (BCS rates; PC group: 99% vs. PS group: 92%, p  =  0.05). @entity66 (OR: 7, 95% Cl, 2.7-18.4, p  =  0.0001) and PC (OR  =  0.2; 95% CI, 0.06-0.72, p  =  0.01) were factors associated with margin positivity in @entity1 treated with BCS. There was no statistically significant difference in 5 year local-recurrence free survival rates between 2 groups. CONCLUSIONS: Our study shows that PC significantly decreases the re-excision in @entity1 undergoing BCS with primary T2 @entity0 . This data suggests that any @entity1 with a @entity5 greater than 2  cm might be considered for PC to increase BCS success with final negative margins.

Preoperative chemotherapy for T2 XXXX is associated with improved surgical outcome.

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor'] @entity0 :: ('MESH:D001943', 'Disease') :: ['breast cancer', 'breast tumors'] @entity66 :: ('MESH:D004194', 'Disease') :: ['Multifocal disease']
@entity0 :: (MESH:D001943,Disease) :: ['breast cancer']
